WO2001026704A3 - Activation ciblee d'un medicament - Google Patents

Activation ciblee d'un medicament Download PDF

Info

Publication number
WO2001026704A3
WO2001026704A3 PCT/IL2000/000637 IL0000637W WO0126704A3 WO 2001026704 A3 WO2001026704 A3 WO 2001026704A3 IL 0000637 W IL0000637 W IL 0000637W WO 0126704 A3 WO0126704 A3 WO 0126704A3
Authority
WO
WIPO (PCT)
Prior art keywords
targeted drug
drug
specific region
drug activation
energy
Prior art date
Application number
PCT/IL2000/000637
Other languages
English (en)
Other versions
WO2001026704A2 (fr
Inventor
Yehuda Yarmut
Original Assignee
Yehuda Yarmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yehuda Yarmut filed Critical Yehuda Yarmut
Priority to AU78150/00A priority Critical patent/AU7815000A/en
Priority to EP00968203A priority patent/EP1221946A4/fr
Priority to IL14891500A priority patent/IL148915A0/xx
Priority to US10/110,038 priority patent/US6576257B1/en
Publication of WO2001026704A2 publication Critical patent/WO2001026704A2/fr
Publication of WO2001026704A3 publication Critical patent/WO2001026704A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds

Abstract

L'invention concerne un procédé servant à administrer un médicament à une zone spécifique du corps d'un patient. Ce procédé consiste à: (a) administrer au patient un promédicament convertible en médicament lorsqu'on l'expose à une dose prédéterminée d'énergie; (b) irradier cette zone spécifique du corps au moyen d'au moins deux ondes d'énergie, chacune étant émise depuis un sens et/ou une distance différents, ce qui permet de générer la dose prédéterminée d'énergie dans la zone spécifique du corps et de convertir le promédicament en médicament dans cette zone spécifique.
PCT/IL2000/000637 1999-10-12 2000-10-10 Activation ciblee d'un medicament WO2001026704A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU78150/00A AU7815000A (en) 1999-10-12 2000-10-10 Targeted drug activation
EP00968203A EP1221946A4 (fr) 1999-10-12 2000-10-10 Activation ciblee d'un medicament
IL14891500A IL148915A0 (en) 1999-10-12 2000-10-10 Targeted drug activation
US10/110,038 US6576257B1 (en) 1999-10-12 2000-10-10 Targeted drug activation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15838399P 1999-10-12 1999-10-12
US60/158,383 1999-10-12

Publications (2)

Publication Number Publication Date
WO2001026704A2 WO2001026704A2 (fr) 2001-04-19
WO2001026704A3 true WO2001026704A3 (fr) 2001-10-18

Family

ID=22567864

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2000/000637 WO2001026704A2 (fr) 1999-10-12 2000-10-10 Activation ciblee d'un medicament

Country Status (5)

Country Link
US (1) US6576257B1 (fr)
EP (1) EP1221946A4 (fr)
AU (1) AU7815000A (fr)
IL (1) IL148915A0 (fr)
WO (1) WO2001026704A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10108798A1 (de) * 2001-02-19 2002-09-26 Laser & Med Tech Gmbh Verfahren und Vorrichtung zur ultraschallgestützten transmembranen Medikamentenapplikation in vivo
US20080033412A1 (en) * 2006-08-01 2008-02-07 Harry Thomas Whelan System and method for convergent light therapy having controllable dosimetry
US20090130017A1 (en) * 2007-11-19 2009-05-21 Searete Llc Targeted short-lived drug delivery
US20090155355A1 (en) * 2007-12-12 2009-06-18 Multi Formulations Ltd. Particles in a capsule
US20100069821A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable medicament release-sites final dosage form
US20100068235A1 (en) * 2008-09-16 2010-03-18 Searete LLC, a limited liability corporation of Deleware Individualizable dosage form
US20100068153A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo activatable final dosage form
US20100068254A1 (en) * 2008-09-16 2010-03-18 Mahalaxmi Gita Bangera Modifying a medicament availability state of a final dosage form
US20100068233A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Modifiable dosage form
US8753677B2 (en) * 2008-09-16 2014-06-17 The Invention Science Fund I, Llc Ex vivo modifiable multiple medicament final dosage form
US20100069887A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Multiple chamber ex vivo adjustable-release final dosage form
US20100068152A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable particle or polymeric based final dosage form
US20100068275A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Personalizable dosage form
US8808733B2 (en) 2009-03-31 2014-08-19 The Board Of Trustees Of The University Of Arkansas Method of controlled drug release from a liposome carrier
US20130261371A1 (en) * 2010-05-03 2013-10-03 University Health Network Imageable activatable agent for radiation therapy and method and system for radiation therapy
US9849087B2 (en) 2011-11-08 2017-12-26 The Board Of Trustees Of The University Of Arkansas Methods and compositions for X-ray induced release from pH sensitive liposomes
WO2015024931A1 (fr) * 2013-08-19 2015-02-26 Moghimi Seyed Moien Composition de nanoadministration peptidique ciblant deux récepteurs
CA2935743A1 (fr) 2014-01-04 2015-07-09 Vijay Agarwal Dispositif et procede a utiliser en therapie photo-dynamique
DK3180085T3 (da) * 2014-08-13 2020-10-26 Convergent R N R Ltd Midler og metoder til målrettet røntgenterapi
CN113677397A (zh) 2019-02-13 2021-11-19 阿尔菲斯医疗股份有限公司 无创声动力学治疗
CN112618550A (zh) * 2021-01-15 2021-04-09 中国医学科学院医药生物技术研究所 抗肿瘤的尿嘧啶类化合物及其脂质组合物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190761A (en) * 1986-08-05 1993-03-02 Liburdy Robert P Electromagnetic field triggered drug and chemical delivery via liposomes
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5780044A (en) * 1994-04-08 1998-07-14 Atrix Laboratories, Inc. Liquid delivery compositions
US5820879A (en) * 1993-02-12 1998-10-13 Access Pharmaceuticals, Inc. Method of delivering a lipid-coated condensed-phase microparticle composition
US6099864A (en) * 1994-12-02 2000-08-08 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration In situ activation of microcapsules

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0090826A1 (fr) * 1981-10-08 1983-10-12 Quentron Optics Pty. Ltd. Ameliorations relatives a la distribution de lumiere pour le traitement de tumeurs
US6090800A (en) * 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US5957960A (en) * 1997-05-05 1999-09-28 Light Sciences Limited Partnership Internal two photon excitation device for delivery of PDT to diffuse abnormal cells

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190761A (en) * 1986-08-05 1993-03-02 Liburdy Robert P Electromagnetic field triggered drug and chemical delivery via liposomes
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5820879A (en) * 1993-02-12 1998-10-13 Access Pharmaceuticals, Inc. Method of delivering a lipid-coated condensed-phase microparticle composition
US5780044A (en) * 1994-04-08 1998-07-14 Atrix Laboratories, Inc. Liquid delivery compositions
US6099864A (en) * 1994-12-02 2000-08-08 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration In situ activation of microcapsules

Also Published As

Publication number Publication date
EP1221946A2 (fr) 2002-07-17
IL148915A0 (en) 2002-09-12
AU7815000A (en) 2001-04-23
US6576257B1 (en) 2003-06-10
WO2001026704A2 (fr) 2001-04-19
EP1221946A4 (fr) 2004-12-22

Similar Documents

Publication Publication Date Title
WO2001026704A3 (fr) Activation ciblee d'un medicament
EP0732106A3 (fr) Amplificateur pour la thérapie de maladies à ultrason contenant des microbulles
AU5367290A (en) Pharmaceutical compositions
AU8115898A (en) Methods of photoacoustic imaging
CA2184242A1 (fr) Systeme de ciblage d'un medicament, procede de preparation et utilisation de ce medicament
WO2001054765A3 (fr) Procede et dispositif permettant d'aligner les faisceaux de radiation medicale a l'aide d'une structure d'immobilisation du patient
CA2149329A1 (fr) Utilisation d'anticorps hybrides et radioisotopiques diriges contre l'antigene de restriction de la differenciation des lymphocytes b humains pour le traitement du lymphome b
CA2288038A1 (fr) Conjugues polyethyleneglycol-interferon alpha, pour la therapie des infections
GB2357969A (en) Improvements in or relating to the treatment of lesions
ATE183920T1 (de) Therapeutisches inhalationspräparat
CA2196237A1 (fr) Extenseur vibrant pour ouvrir des lesions calcifiees
WO2001007110A3 (fr) Appareil et procede destines au traitement electrique ou medicamenteux des tissus cellulaires
AU7735200A (en) Treatment of tissue by application of energy and drugs
CA2214503A1 (fr) Methode de traitement de tumeurs
EP0352477A3 (fr) Utilisation de l'adénosine-5'-phosphate dans le traitement de cancer cachexia
EP1702618A3 (fr) Compositions et utilisations de et743 en therapie combinée pour traiter le cancer
CA2294921A1 (fr) Levobupivacine et son utilisation
WO1999022722A3 (fr) Utilisation de macrolides pour le traitement du cancer et de la degenerescence maculaire
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
EP1304108A3 (fr) Compositions pour traiter l'arythmie et procédés de traitement
AU4942393A (en) Use of ribose in the preparation of a drug for use in the treatment of decrease in body performance, in particular organ insufficiency
EP0429522A4 (en) Phosphosugar-based anti-inflammatory and/or immunosuppressive drugs
WO2000010590A3 (fr) Traitement anticancereux
EP0811385A3 (fr) Conjugué d'un facteur reconnaissant spécifiquement le récepteur interleukin-2, avec la ribonucléase
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 148915

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 10110038

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2000968203

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000968203

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWR Wipo information: refused in national office

Ref document number: 2000968203

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000968203

Country of ref document: EP